questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-1 de cytochromes P450
Cytochrome P-450 CYP1B1
Cytochrome P-450 CYP1B1 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP1B1 : Questions médicales les plus fréquentes",
"headline": "Cytochrome P-450 CYP1B1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cytochrome P-450 CYP1B1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-12",
"dateModified": "2025-03-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP1B1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Famille-1 de cytochromes P450",
"url": "https://questionsmedicales.fr/mesh/D000072461",
"about": {
"@type": "MedicalCondition",
"name": "Famille-1 de cytochromes P450",
"code": {
"@type": "MedicalCode",
"code": "D000072461",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.100"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP1B1",
"alternateName": "Cytochrome P-450 CYP1B1",
"code": {
"@type": "MedicalCode",
"code": "D065633",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Purnima Singh",
"url": "https://questionsmedicales.fr/author/Purnima%20Singh",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Shubha Ranjan Dutta",
"url": "https://questionsmedicales.fr/author/Shubha%20Ranjan%20Dutta",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Chi Young Song",
"url": "https://questionsmedicales.fr/author/Chi%20Young%20Song",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Frank J Gonzalez",
"url": "https://questionsmedicales.fr/author/Frank%20J%20Gonzalez",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)."
}
},
{
"@type": "Person",
"name": "Kafait U Malik",
"url": "https://questionsmedicales.fr/author/Kafait%20U%20Malik",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Fetal brain biometry and cortical development after maternal SARS-CoV-2 infection in pregnancy: A prospective case-control study.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/36305509",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jcu.23382"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative analysis of a novel spectral-domain OCT biometer versus swept-source OCT or OLCR biometer in healthy pediatric ocular biometry.",
"datePublished": "2024-10-24",
"url": "https://questionsmedicales.fr/article/39448792",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-77177-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of axial length and anterior segment parameters of patients with myopia measured using 2 fourier-domain optical coherent biometry devices.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39014346",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-024-03546-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hydrogel Containing Silibinin-Loaded Pomegranate Oil-Based Nanocapsules for Cutaneous Application: In Vitro Safety Investigation and Human Skin Biometry and Permeation Studies.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37349650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1208/s12249-023-02606-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of first trimester ultrasound fetal biometry ratios femur length/biparietal diameter, femur length/abdominal circumference and femur length/foot for the screening of skeletal dysplasia.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36575575",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pd.6295"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-1 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Cytochrome P-450 CYP1B1",
"item": "https://questionsmedicales.fr/mesh/D065633"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cytochrome P-450 CYP1B1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cytochrome P-450 CYP1B1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cytochrome P-450 CYP1B1",
"description": "Comment diagnostiquer une anomalie de CYP1B1 ?\nQuels tests sont utilisés pour évaluer CYP1B1 ?\nQuels symptômes indiquent un problème avec CYP1B1 ?\nY a-t-il des marqueurs biologiques pour CYP1B1 ?\nLe diagnostic de CYP1B1 est-il complexe ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cytochrome P-450 CYP1B1",
"description": "Quels symptômes sont liés à une mutation de CYP1B1 ?\nLes symptômes de CYP1B1 varient-ils selon les individus ?\nCYP1B1 peut-il affecter le métabolisme des médicaments ?\nQuels signes cliniques sont associés à CYP1B1 ?\nLes symptômes de CYP1B1 sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cytochrome P-450 CYP1B1",
"description": "Comment prévenir les troubles liés à CYP1B1 ?\nLe mode de vie influence-t-il CYP1B1 ?\nDes vaccinations peuvent-elles aider avec CYP1B1 ?\nLe suivi médical régulier est-il important pour CYP1B1 ?\nLes conseils génétiques sont-ils utiles pour CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cytochrome P-450 CYP1B1",
"description": "Quels traitements existent pour les troubles liés à CYP1B1 ?\nPeut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?\nY a-t-il des traitements préventifs pour CYP1B1 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nDes thérapies alternatives sont-elles disponibles pour CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cytochrome P-450 CYP1B1",
"description": "Quelles complications peuvent survenir avec CYP1B1 ?\nLes complications de CYP1B1 sont-elles graves ?\nComment gérer les complications liées à CYP1B1 ?\nLes complications de CYP1B1 sont-elles prévisibles ?\nY a-t-il des complications à long terme avec CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cytochrome P-450 CYP1B1",
"description": "Quels sont les facteurs de risque pour CYP1B1 ?\nL'hérédité joue-t-elle un rôle dans CYP1B1 ?\nL'exposition à des toxines influence-t-elle CYP1B1 ?\nLe sexe influence-t-il les risques liés à CYP1B1 ?\nL'alimentation a-t-elle un impact sur CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Biometry&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de CYP1B1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses enzymatiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer CYP1B1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de métabolisme des médicaments et les analyses sanguines sont courants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec CYP1B1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des troubles métaboliques ou des réactions médicamenteuses peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques pour CYP1B1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de certains métabolites peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Le diagnostic de CYP1B1 est-il complexe ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être complexe, nécessitant une évaluation clinique et des tests spécialisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une mutation de CYP1B1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles oculaires, des anomalies de développement et des cancers peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes de CYP1B1 varient-ils selon les individus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la gravité de la mutation."
}
},
{
"@type": "Question",
"name": "CYP1B1 peut-il affecter le métabolisme des médicaments ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dysfonction de CYP1B1 peut entraîner des réactions indésirables aux médicaments."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à CYP1B1 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des troubles de la vision et des anomalies cutanées peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les symptômes de CYP1B1 sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à CYP1B1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut le dépistage génétique et l'éducation sur les risques."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il CYP1B1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire les risques de complications liées à CYP1B1."
}
},
{
"@type": "Question",
"name": "Des vaccinations peuvent-elles aider avec CYP1B1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles liés à CYP1B1."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important pour CYP1B1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les complications."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour CYP1B1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à comprendre les risques et à planifier des mesures préventives."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles liés à CYP1B1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements de dosage et des alternatives médicamenteuses peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs pour CYP1B1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques et un suivi régulier peuvent être des mesures préventives."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour tous les patients ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements peut varier selon la gravité de la condition."
}
},
{
"@type": "Question",
"name": "Des thérapies alternatives sont-elles disponibles pour CYP1B1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent être explorées, mais leur efficacité n'est pas prouvée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CYP1B1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des cancers et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications de CYP1B1 sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être graves et nécessiter une intervention médicale."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à CYP1B1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical, des traitements symptomatiques et des interventions."
}
},
{
"@type": "Question",
"name": "Les complications de CYP1B1 sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles avec un suivi approprié."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme avec CYP1B1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour CYP1B1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et l'exposition environnementale."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans CYP1B1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations de CYP1B1 peuvent être héritées, augmentant le risque de troubles."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines influence-t-elle CYP1B1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut affecter l'activité de CYP1B1."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il les risques liés à CYP1B1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que le sexe peut influencer l'expression de CYP1B1."
}
},
{
"@type": "Question",
"name": "L'alimentation a-t-elle un impact sur CYP1B1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires peuvent influencer l'activité de CYP1B1 et le métabolisme."
}
}
]
}
]
}
To assess cerebral growth and the development of fetal cortex using neurosonography in fetuses from pregnancies experiencing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) according to i...
Pregnancies with by SARS-CoV-2 during first and second trimesters were prospectively studied and matched with unaffected controls. Enclosed women underwent neurosonography at 30-34 weeks of gestation ...
One hundred and seventy four consecutive pregnancies experiencing SARS COV 2 infection (81 before 14 weeks and 93 later) and 131 not affected pregnancies were considered. General and pregnancy charact...
SARS-CoV-2 infection does nor resulted associate with differential fetal cortical development or brain growth in mildly symptomatic pregnant women. This information may be useful to reassure infected ...
With the advancements in ocular biometric technology, there have been significant improvements in accurately and efficiently measuring ocular parameters. The aim of this study is to compare the reliab...
This study assessed the agreement of ocular parameters of patients with myopia measured using Colombo intraocular lens (IOL) 2 and IOLMaster 700....
Eighty patients (male, 22; average age, 29.14 ± 7.36 years) with myopia (159 eyes) were included in this study in May 2023. The participants' axial length (AXL), central corneal thickness (CCT), lens ...
With the Colombo IOL 2, lower values for K2 and J0 (odds ratio [OR] = 0.587, p = 0.033; OR = 0.779, p < 0.0001, respectively), and larger values for WTW, Astig, and J45 (OR = 1.277, OR = 1.482, OR = 1...
In young patients with myopia, CCT and AXL measurements obtained with the Colombo IOL 2 and IOLMaster 700 were comparable. However, WTW, LT, corneal refractive power, and astigmatism values could not ...
In previous studies, we developed a hydrogel formulation containing silibinin-loaded pomegranate oil nanocapsules (HG-NCSB) that had improved in vivo anti-inflammatory action in comparison to non-enca...
Skeletal dysplasia is usually apparent in the second trimester. First trimester femur-length/biparietal diameter (FL/BPD), FL/abdominal circumference (AC) and FL/foot for the screening of skeletal dys...
Case-control study: pregnancies with molecular confirmation of skeletal dysplasia undergoing nuchal translucency (January_2007-December_2021). Controls included pregnancies without fetal abnormalities...
Twenty-eight skeletal dysplasia cases were identified; 17 (60.71%) corresponded to lethal types. Compared to 184 controls, cases had a lower median FL/BPD (0.34 [IQR 0.30-0.38] vs. 0.44 [IQR 0.39-0.48...
First trimester FL/BPD and FL/foot may be of clinical utility in the detection of skeletal dysplasia especially when there is another suspicious sonographic sign or when there is a relevant family his...
This study investigated the difference between the calculation of cycloplegic crystalline lens power (LP) using non-cycloplegic and cycloplegic biometry data in children, and associated factors were e...
A total of 821 children were enrolled and only right eye was analyzed. The corneal radii (CR), corneal power (CP), anterior chamber depth (ACD), lens thickness (LT), and axial length (AL) before and a...
The mean age of the 821 subjects was 9.83 ± 2.97 years with a mean spherical equivalent refraction (SER) of - 1.06 ± 2.12 D. Overall, the ACD, LT, and ASL were significantly affected by cycloplegia ag...
Our results indicated that using cycloplegic biometry could lead to an overestimation in LP for low and moderate myopia eyes. This finding is likely to facilitate the refractive development research i...
ClinicalTrials.gov identifier, NCT05247099....
We assessed the accuracy of two portable ultrasound machines (PUM) in obtaining fetal biometry and estimating gestational age....
We analyzed data from the Fetal Age Machine Learning Initiative, an observational study of pregnant women in the United States and Zambia. Each participant underwent assessment by an experienced sonog...
881 participants contributed 1386 paired PUM-HSUM ultrasound studies between April and December 2021. PUM studies included 991 Butterfly and 395 Clarius. Gestational age at scan ranged from 7 to 38 we...
Both the Butterfly iQ and Clarius C3 PUM devices were highly accurate in performing fetal biometry in a diverse population from the US and Zambia. This article is protected by copyright. All rights re...
To describe a repeatable method of measuring ocular structures and to establish ocular biometry reference ranges in adult domestic rabbits (Oryctolagus cuniculus) without medical history or imaging fi...
In this retrospective and observational anatomic study, 100 eyes from 50 rabbits without medical history or imaging findings consistent with ophthalmic disease who received a head computed tomography ...
A reference guide was established, with globe width being the largest dimension (18.03 ± 0.81 mm), followed by height (17.18 ± 0.69 mm) and then length (16.64 ± 0.66 mm). Increased weight was associat...
CT is a reliable modality for measurement of ocular biometry dimensions in rabbits. These reference values can be applied to aid in identifying diseases that affect the dimensions of the ocular struct...
High-precision biometry and accurate intraocular lens (IOL) power calculation have become essential components of cataract surgery. In clinical practice, IOL power calculation involves measuring param...